Literature DB >> 6467152

Management of Hodgkin's disease in western India.

K A Dinshaw, S H Advani, R Gopal, C N Nair, G V Talvalkar, P Gangadharan, P B Desai.   

Abstract

The authors report a retrospective analysis of 441 patients with Hodgkin's disease seen at the Tata Memorial Hospital, Bombay, over a 4-year period from 1975 to 1978. Clinicopathologic features seem to vary from those reported in the western literature, but are similar to the patterns observed in Africa and South America. Thirty-three percent of all malignant lymphomas were Hodgkin's disease. Histologically, the mixed cell (MC) type (40%) and the lymphocytic predominant (LP) type (24%) were the most common, with 52% of patients presenting in Stages III and IV. The nodular sclerosis (NS) variant occurred in only 11% of the cases. Systemic symptoms were present in 24% of clinical Stage I patients, and increased steadily to 85% in Stage IV patients. Bone marrow biopsies in 242 patients were found to be of little value in Stages I and II. Thirty of 34 patients with positive bone marrow biopsy were in clinical Stages III B and IV, whereas 24 of 34 patients showed MC and LD patterns. Lymphangiography in 104 patients altered the clinical staging of Stages I and II in 27% of the cases with accuracy of 80%. Staging laparotomy performed in 93 patients altered the stage in 45% of clinical Stage I and 62% of Stage II patients. Splenic involvement was common in the presence of systemic symptoms (67%) and MC/LD histology (82%). The incidence of liver involvement was 16% in 15 patients with all, but one, associated with splenic pathology. The clinical stage and histopathologic variants of the disease bear an excellent correlation with a significant impact on treatment responses and total survival. The survival rates for Stage I were 81%, Stage II 76%, Stage IIIA 71%, and Stage IIIB and IV 46% at 48 months. The LP type had the best prognosis with 85% survival at 48 months, whereas the survival in the depleted variety was only 56%. Surprisingly, the MC type did better with a 64% survival, while the nodular sclerosis group had 59% surviving at 48 months.

Entities:  

Mesh:

Year:  1984        PMID: 6467152     DOI: 10.1002/1097-0142(19841001)54:7<1276::aid-cncr2820540708>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Lympho-hemopoietic malignancies in India.

Authors:  Manisha Bhutani; Amish Vora; Lalit Kumar; Vinod Kochupillai
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Comprehensive epidemiological and clinicopathological survey of Hodgkin's disease in Hungary.

Authors:  E Berényi; G Szegedi; K Szabó; L István; G Radványi; S Berkessy; M Zöllei; G Varga; Z Nemes; G Kelényi
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.

Authors:  Dinesh Bhurani; Reena Nair; Senthil Rajappa; Suparna Ajit Rao; Nithya Sridharan; Rakesh Reddy Boya; Ganapathi S Raman; Hari Menon; Arun Seshachalam; Ramesh Nimmagadda
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

4.  Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.

Authors:  H Jain; M Sengar; R Nair; H Menon; S Laskar; T Shet; S Gujral; E Sridhar
Journal:  J Postgrad Med       Date:  2015 Apr-Jun       Impact factor: 1.476

5.  Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution.

Authors:  Rahul Narayan Maddi; Vijay Gandhi Linga; Kalpathi Krishnamani Iyer; Joseph Stalin Chowdary; Sadashivudu Gundeti; Raghunadharao Digumarti; Tara Roshini Paul
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Oct-Dec

6.  Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.

Authors:  Arun Seshachalam; Shashidhar V Karpurmath; Krishnakumar Rathnam; S Ganapathi Raman; Murugesan Janarthinakani; Krishna Prasad; Channappa Patil; Parameswaran Anoop; Neelesh Reddy; Satish Kumar Anumula; Sirigeri Prabhakar Roopa; Krishna Reddy Golamari; Madhav Danthala; Prasad Gunari; Basawantrao Malipatil; Bharath Rangarajan; Karthik S Udupa; Manjunath Nandennavar; Kesavan Niraimathi; Hemant Deepak Shewade
Journal:  J Glob Oncol       Date:  2019-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.